PDCD1 and digestive system neoplasm: Currently, immune checkpoint inhibitors (ICIs) such as anti–PD-1/PD-L1 antibodies have shown robust efficacy in a subset of GI tumors with high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR) (2).